美国药企3.5亿美元预付款引进一款减重药,新靶点胰淀素潜力多大?

澎湃新闻
04 Mar

又有跨国药企进入减重赛道,减肥新靶点再获关注。  3月3日,美国生物制药企业艾伯维宣布,与丹麦生物科技公司Gubra达成共同开发GUB014295的许可协议。这款在研产品处于一期临床研究阶段。根据协议条款,艾伯维将在全球范围内主导GUB014295的开发和商业化活动。Gubra将获得总额为3.5亿美元的预付款,并有资格获得18.75亿美元的开发、商业和销售里程碑付款,以及全球净销售额的分级版税。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10